The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer.

J Clin Med · 2020 · PMC7356188 · PMID 32575417

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

MET FISH analysis showed no benefit of onartuzumab, while EGFR -mutated patients showed a trend toward short OS when treated with onartuzumab (HR: 4.68; 95% CI: 0.97–22.63).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The benefit that appeared in these studies was clinically significant but did not reach statistical significance in all cases.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.